Zhi Tong Cai Jing·2026-01-15 00:49Core Insights - WuXi AppTec (603259.SH, 02359) presented at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, updating on its business progress [1] - As of Q3 2025, the company has a total of 3,430 small molecule CDMO pipelines, representing 16% of the global clinical-stage new drug pipelines, with 167 projects in Phase III and commercialization [1] - The number of Phase III and commercial projects has increased from 107 in 2022 to 167, marking a growth of 56%, with corresponding revenue rising from 4.7 billion yuan to an expected 10.3 billion yuan in 2024, potentially reaching a new high this year [1] Industry Trends - Oral medications are rapidly replacing injectables in mainstream treatment areas due to their convenience, becoming a new focus in the pharmaceutical industry [1] - Industry media, Endpoints News, has identified "Pills" as a key term for 2025, indicating the strong rise of this sector, with oral formulations expanding in areas such as obesity, heart disease, and inflammatory diseases, capturing market share previously dominated by large molecule biologics [1]